泽泻是一味具有多种用途的中药,在中国已有很长的应用历史。早期的临床研究已初步证明泽泻提取物可能是良好的调血脂药物,现代药理学研究发现其可能具有抗动脉粥样硬化作用,已有的安全性评价实验发现泽泻提取物肝肾毒性小,适合长期用药。从已发表的泽泻有关调血脂药效的文献出发,对泽泻的作用机制、药效成分、药动学、临床疗效以及安全性进行综述。泽泻原萜烷三萜类成分泽泻醇A、泽泻醇A 24-乙酸酯等是其调血脂活性物质基础。

Alismatis Rhizoma, as a Chinese materia medica with multiple uses, has a long history of application in China. By retrieving the published literature of hypolipidemic effect, this review presents an overview of Alismatis Rhizoma, including chemistry, pharmacological mechanisms, clinical application, and safety evaluation. The protostane triterpenoids, as alisol A and alisol A 24-acetate, had hypolipidemic effects. Early preliminary clinical studies have shown that the Alismatis Rhizoma extraction may be a good hypolipidemic drug. Modern pharmacologic study found that it had anti-atherosclerotic effects. The reported safety evaluation results showed that the extraction was with low liver and kidney toxicity and might be suitable for long term use. We think it is worth to be developed a new drug.

上海市科委中药现代化专项(12401901300)